Got it. Dianthus Therapeutics, Inc. hiring Head of Investor Relations and Clackamas, OR, Compassion & Choices - The forward-looking statements included in this press release represent Speros views as of the date of this press release. Referrals increase your chances of interviewing at Avidity Biosciences, Inc. by 2x. Salary.com's CompAnalyst platform offers: These charts show the average hourly wage (core compensation), as well as the average total hourly cash compensation for the job for Investor Relations Administrator in companies like SPERO THERAPEUTICS INC in the United States. This afternoon, Spero Therapeutics released financial results and provided a pipeline update for the first quarter of 2023. Stock information, SEC filings, corporate governance, IR resources and more. Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing May 31, 2023 16:05 ET A key goal of the trial is to show SPR720 driving an early microbiological response as a standalone agent versus placebo with the primary endpoint evaluating changes in bacterial load and sputum samples from baseline. We outlined our clinical programs in detail only six weeks ago on our last earnings call. Managing and optimizing the firm's investor CRM database (Juniper Square) and investor listsAt least one year of experience in investor relations, communications, or marketing, preferably at Lucid Motors - Newark NY. Yes. The office building will be on the right hand side of Massachusetts Ave on the corner of Massachusetts Ave and Prospect Street. And then finally, in our in vivo and in vitro models show, weve demonstrated that SPR720 has the potency to address a large range of NTM pathogens, which is what these patients need. So if you were to assume that we expect to get milestones to jumpstart the trial and those will be more than sufficient to initiate the trial on its rollout. Supervises and directs subordinates staff. Your submission has been received! Spero Therapeutics The base salary for Investor Relations Manager in companies like SPERO THERAPEUTICS INC range from $123,587 to $174,438 with the average base salary of $153,699. What does an Investor Relations Administrator do at companies like SPERO THERAPEUTICS INC? Sustainable Talent - Santa Clara Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Speros ability to timely complete the NDA submission to the FDA for tebipenem HBr; Speros need for additional funding; the lengthy, expensive, and uncertain process of clinical drug development; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; Speros reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; the ability to develop and commercialize Speros product candidates, if approved; the potential impact of the COVID-19 pandemic; Speros ability to retain key personnel and to manage its growth; whether Speros cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the Risk Factors set forth in filings that Spero periodically makes with the U.S. Securities and Exchange Commission. One is that, ARIKAYCE is a different drug. SPERO THERAPEUTICS Exit 18. We believe pairing a positive result on this primary endpoint with supportive evidence and learning from the trial secondary endpoints will enable us to substantially de-risk the program and move confidently to late-stage development. Please go ahead. Based on our current operating plan, we believe our cash and cash equivalents together with other non-dilutive funding commitments will be sufficient to fund our operating expenses and capital expenditure requirements beyond 2024. Good afternoon, and welcome to the Spero Therapeutics First Quarter 2023 Financial Results Conference Call. And specifically, how they might feed into what youre thinking about for the pivotal endpoint, especially, given the additional, I wouldnt call it clarity, but the additional information on how ARIKAYCE may be approaching its frontline PRO primary endpoint. WebContact Spero Therapeutics Investor Contact: IR@sperotherapeutics.com Media Contact Media@sperotherapeutics.com Business Development Contact: BD@sperotherapeutics.com General Inquires: info@sperotherapeutics.com or at 857-242-1600 Office Location: 675 Massachusetts Avenue 14th Floor Cambridge, MA 02139 WebSpero Therapeutics (NASDAQ:SPRO) adds US$10m to market cap in the past 7 days, though investors from a year ago are still down 85%. Well, and Ill say that weve enjoyed our collaboration with Pfizer and benefited from their expertise and perspective. When expanded it provides a list of search options that will switch the search inputs to match the current selection. We also expect the licensing agreement for SPR206 will be key to expanding global access to this important candidate, as Pfizer is uniquely positioned to successfully commercialize this asset in the Pfizer territories (ex-U.S. and ex-Asia). From Logan Airport via MBTAComing from Logan Airport, take the Silver Line to South Station, transfer to the Red Line and get off at Central Square. Hourly rate can vary widely depending on many important factors, including education, certifications, additional skills, the number of years you have spent in your profession. JOB DESCRIPTION Nxu is seeking an experienced Director of Investor Relations to manage relationships with our shareholders, analysts, and investors including retail and institutional. Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories in exchange for potential development and commercial milestone payments and royalties. Stimulating. Spero Therapeutics We will now open the call for the Q&A. Manage Analyst Expectations, both Buy-Side and Sell-Side: Monitor market and industry trends Investor Relations Manager in Grand Rapids, MI. Second is that our Phase 1 data as well as our tox data to date suggest its a well-tolerated drug and that has the potential to be a preferred option for these patients. Spero Therapeutics Investor Relations Manager in Temple, TX. WebInvestor Relations Stock information, SEC filings, corporate governance, IR resources and more. Spero Therapeutics is committed to advancing novel treatment approaches for bacterial infections. 2022 Spero Therapeutics. The products discussed herein may have different labeling in different countries. The two parties have also entered into a licensing agreement for SPR206, Speros intravenously (IV)-administered next-generation polymyxin product candidate being developed to treat serious multi-drug resistant (MDR) Gram-negative infections in the hospital setting. Investors Thank you. Being an Investor Relations Manager plans the annual meeting and meeting documents, such as the annual report and the proxy statement, in accordance with SEC regulations. Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. Challenging. By: Cristina Larkin and David Melnick, MD. Turning our attention to our remaining financial results. Turn right onto Massachusetts Ave. Take River Street to Massachusetts Ave in Cambridge. Based on our compensation data, the estimated salary potential for Investor Relations Administrator will increase 16 % over 5 years. Thanks for the question, Ritu. Director, Investor Relations - LinkedIn In addition, we believe the strong characteristics of SPR206 position this potential medicine to complement our pipeline and portfolio of antimicrobial products, and we look forward to its continued clinical development.. How much does an Investor Relations Manager make at companies like SPERO THERAPEUTICS INC in the United States? In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP. In some cases, forward-looking statements can be identified by terms such as may, will, should, expect, plan, aim, anticipate, could, intent, target, project, contemplate, believe, estimate, predict, potential or continue or the negative of these terms or other similar expressions. The average hourly rate for Investor Relations Administrator in companies like SPERO THERAPEUTICS INC range from $42 to $58 with the average hourly pay of $50. Typically reports to top management. Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.88. Explore Investor Resources Careers Collaborative. These forward-looking statements should not be relied upon as representing Speros views as of any date subsequent to the date of this press release. Im pleased to report that the program continues to advance according to plan. We look forward to collaborating with Pfizer on the continued advancement of this asset., There is a pressing unmet need for effective medicines to address antimicrobial resistant infections, and Pfizer is dedicated to meeting this global health challenge through scientific research, collaboration, and strategic investment, added Annaliesa Anderson, Chief Scientific Officer of Bacterial Vaccines and Hospital, Pfizer. Nontuberculous Mycobacteria (NTM) Infections. The total hourly cash compensation, which includes base and short-term incentives, can vary anywhere from $45 to $66 with the average total hourly cash compensation of $55. Novel Treatment Development For Multi-Drug - Spero Corporate Communications and Investor Relations Coordinator SPRO - key executives, insider trading, ownership, revenue and average growth rates. Spero Therapeutics Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States.